• Explore /
  • Poster
  • / INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Abstract Video & Slides Poster

Authors

Aaron Richard Hansen

Aaron Richard Hansen

Princess Margaret Cancer Centre, Toronto, ON, Canada

Aaron Richard Hansen , Thomas S. Stanton , Min Hee Hong , Ezra E.W. Cohen , Hisham Mohamed Mehanna , Michael Jon Chisamore , David Turner , Sapna Yadavilli , Kelly Bell , Carlos Baccan , Rosalida Leone , Helen Chen , Helen Zhou , Catherine Elizabeth Ellis , Marc S. Ballas , Axel Hoos , Danny Rischin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04128696

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS6591)

DOI

10.1200/JCO.2020.38.15_suppl.TPS6591

Abstract #

TPS6591

Poster Bd #

252

Abstract Disclosures

Similar Posters

First Author: Lillian L. Siu

First Author: Ezra E.W. Cohen

First Author: Jared Cohen

First Author: Danny Rischin